Maraviroc Intensification Modulates Atherosclerotic Progression in HIV-Suppressed Patients at High Cardiovascular Risk. A Randomized, Crossover Pilot Study | Zendy

Daniela Francisci | Zendy; Matteo Pirro | Zendy; Elisabetta Schiaroli | Zendy; Massimo R. Mannarino | Zendy; Sabrina Cipriani | Zendy; Vanessa Bianconi | Zendy; Alessia Alunno | Zendy; Francesco Bagaglia | Zendy; Onelia Bistoni | Zendy; Emanuela Falcinelli | Zendy; Loredana Bury | Zendy; Roberto Gerli | Zendy; Elmo Mannarino | Zendy; Raffaele De Caterina | Zendy; Franco Baldelli | Zendy

Open Access

Maraviroc Intensification Modulates Atherosclerotic Progression in HIV-Suppressed Patients at High Cardiovascular Risk. A Randomized, Crossover Pilot Study

Author(s) -

Daniela Francisci,

Matteo Pirro,

Elisabetta Schiaroli,

Massimo R. Mannarino,

Sabrina Cipriani,

Vanessa Bianconi,

Alessia Alunno,

Francesco Bagaglia,

Onelia Bistoni,

Emanuela Falcinelli,

Loredana Bury,

Roberto Gerli,

Elmo Mannarino,

Raffaele De Caterina,

Franco Baldelli

Publication year - 2019

Publication title -

open forum infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.546

H-Index - 35

ISSN - 2328-8957

DOI - 10.1093/ofid/ofz112

Subject(s) - maraviroc , medicine , pulse wave velocity , arterial stiffness , endothelial dysfunction , systemic inflammation , cardiology , inflammation , immunology , human immunodeficiency virus (hiv) , blood pressure

Maraviroc led to significant improvements in several markers for cardiovascular risk, endothelial dysfunction, arterial stiffness, and early carotid atherosclerosis, which was accompanied by an increase of vascular competence, without seeming to affect systemic inflammation. Our data support the need for larger studies to test for any effects of maraviroc on preventing atherosclerosis-driven pathologies.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research